319 results about "Cytotoxic T cell" patented technology

The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.

The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

The present invention is drawn to methods for measuring numbers, levels, and/or ratios of cells, such as lymphocytes, infiltrated into a solid tissue, such as a tumor or a tissue affected by an autoimmune disease, and to methods for making patient prognoses based on such measurements. In one aspect, methods of the invention comprise sorting lymphocytes from an accessible tissue, such as peripheral blood, into functional subsets, such as cytotoxic T cells and regulatory T cells, and generating clonotype profiles of each subset. An inaccessible disease-affected tissue is sampled and one or more clonotype profiles are generated. From the latter clonotype profiles, levels lymphocytes in each of the functional subsets are determined in the disease-affected tissue by their clonotypes, which are identified from lymphocytes sorted into subsets from the accessible tissue.

The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.

A genetically disabled mutant virus has a genome which is defective in respect of a selected gene that is essential for the production of infectious new virus particles, and which carries heterologous genetic material encoding an immunomodulatory protein such as GM-CSF, IL-2, or others, such that the mutant virus can infect normal host cells and cause expression of immunomodulatory protein, but the mutant virus cannot cause production of infectious new virus particles except when the virus infects recombinant complementing host cells expressing a gene that provides the function of the essential viral gene; the site of insertion of the heterologous genetic material encoding the immunomodulatory protein preferably being at the site of the defect in the selected essential viral gene. Uses include prophylactic and therapeutic use in generating an immune response in a subject treated therewith; use in the preparation of an immunogen such as a vaccine for use in tumor therapy; use in the in-vitro expansion of (e.g. virus-specific) cytotoxic T cells; and therapeutic or prophylactic use in corrective gene therapy.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the most commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine composiitons comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject.

Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.

Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease.

An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.

MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-gamma-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses hereof.

The present invention relates to methods and compositions of activating cytotoxic T lymphocytes (CTLs) in vivo with specificity for particular antigenic peptides, and to methods and compositions of using activated CTLs in vivo for the treatment of a variety of disease conditions. In some preferred embodiments, the invention provides methods of employing a polypeptide of the amino acid sequence VMAGVGSPYV to specifically activating CTLs in subjects having a breast cancer overexpressing a Her-2/Neu protein, and methods of using the polypeptide to treat such subjects.

The present invention is a method for inducing cytotoxic T cell having an antigen-specific cytotoxic activity, a method for maintaining the cell, a method for continuously culturing the cell or a method for expanding the cell, comprising the step of culturing a cytotoxic T cell in the presence of at least one substance selected from the group consisting of (A) a substance having a binding activity to CD44; (B) a substance capable of regulating a signal emitted by binding a CD44 ligand to CD44; (C) a substance capable of inhibiting binding of a growth factor to a growth factor receptor; (D) a substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor; and (E) fibronectin, a fragment thereof or a mixture thereof.

The present invention relates to a novel method and formulation for the induction of immune responses against polypeptide antigens. In particular, the invention provides a method and formulation for induction of cytotoxic T cell responses against a polypeptide antigen of choice. The formulations are characterized by containing chitosan in admixture with the polypeptide antigen, preferably in the form of microparticles that may be cross-linked.

The present invention provides methods for directing the immune response of an animal towards immunologically weak or rare antigens such as tumor antigens. The methods combine subtractive immunization with hyperimmunization and result in the controlled or directed production of target-specific antibodies, helper T cells (CD4⁺-T lymphocytes) and cytotoxic T cells (CD8⁺-T lymphocytes). Also provided by the present invention are untransformed and transformed cell lines, and growth media necessary to grow the untransformed cell line in a differentiated state. Monoclonal antibodies which react with different neoplastic cell lines and hybridomas producing such antibodies are also provided.

The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.

Provided in certain embodiments are methods for pairing patient cells and donor cells to prepare cytotoxic T cells, either in vitro or, when their formation is induced in a subject, in vivo. Such cytotoxic T cells could be administered to the patient for treating certain disorders, such as a cancer (for example, brain cancer).

The invention relates to immunoconjugates of formula: A-B-(C)n where B may be present or absent, A is a specific binding protein such as an antibody or an antibody binding fragment, or a ligand binding to a receptor present on target cells B comprises at least one molecule to which "A" and "C" bind, such as an avidin/streptavidin complex, "C" is an MHC molecule, and "n" is a whole number ranging from 1 to 10. The conjugates provide the exquisite binding specificity of antibodies, combined with an ability to stimulate cytotoxic T cells to identify and to destroy cells on which the conjugate is bound and oligomerized. The conjugates are useful both therapeutically and diagnostically.

The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.